Search Results - "Brown, Chloe K"

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer by Inglis, Daniel J, Lavranos, Tina C, Beaumont, Donna M, Leske, Annabell F, Brown, Chloe K, Hall, Allison J, Kremmidiotis, Gabriel

“…BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates…”
Get full text

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival by Inglis, Daniel J., Lavranos, Tina C., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a compound that exerts an anti-cancer action through selective destruction of tumor blood vessels. A single IV dose of BNC105 causes a very high…”
Get full text

Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics by Lavranos, Tina C., Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a small molecule Vascular Disrupting Agent (VDA) that exerts anti-cancer activity through selective shut-down of tumor blood vessels. A single dose…”
Get full text

Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer by Lavranos, Tina C., Leske, Annabell F., Inglis, Daniel J., Brown, Chloe K., Bibby, David C., Kremmidiotis, Gabriel

“…BNC105 is a small molecule that exerts anti-cancer activity through disruption of tubulin polymerization. BNC105 is unique in its ability to selectively block…”
Get full text